Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.
Respiratory syncytial virus (RSV) causes acute exacerbations in COPD and asthma. RSV infects bronchial epithelial cells (HBE) that trigger RSV associated lung pathology. This study explores whether the phosphodiesterase 4 (PDE4) inhibitor Roflumilast N-oxide (RNO), alters RSV infection of well-diffe...
Guardado en:
Autores principales: | Manuel Mata, Isidoro Martinez, Jose A Melero, Herman Tenor, Julio Cortijo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eeffae9a83494ce4973afe8664160734 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The larger attachment glycoprotein of respiratory syncytial virus produced in primary human bronchial epithelial cultures reduces infectivity for cell lines.
por: Tiffany King, et al.
Publicado: (2021) -
Role of CCR3 in respiratory syncytial virus infection of airway epithelial cells
por: Vincent Wellemans, et al.
Publicado: (2021) -
Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung
por: Numata M, et al.
Publicado: (2013) -
Meteorological drivers of respiratory syncytial virus infections in Singapore
por: Sheikh Taslim Ali, et al.
Publicado: (2020) -
Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
por: Amparo Buenestado, et al.
Publicado: (2013)